Howe & Rusling’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Howe & Rusling’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-200	Closed	-$6K	–	1240
2022 Q2	$6K	Buy	+200	New	+$5.86K	﹤0.01%	630

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Howe & Rusling's GBT Position: Q3 2022 in Review

Howe & Rusling sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 200 shares — an estimated $6K sold.

Howe & Rusling first reported a position in GBT in Q2 2022 and held it in 1 quarter. The position peaked at $6K in Q2 2022. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

Howe & Rusling reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
Howe & Rusling sold 200 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $6K.
Howe & Rusling first reported a position in Global Blood Therapeutics, Inc. in Q2 2022 and held it in 1 quarter.
Howe & Rusling's Global Blood Therapeutics, Inc. position peaked at $6K in Q2 2022.
247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Howe & Rusling's 13F filing for Q3 2022, filed 14 Nov 2022.